Heartflow Revenue Soars 39.7%, IPO Boosts Cash Amid Widening Losses

TL;DR

**HTFL's revenue growth is impressive, but the ballooning net loss and warrant liability are red flags; the IPO cash infusion is a temporary fix, not a cure for underlying profitability issues.**

AI Summary

Heartflow, Inc. (HTFL) reported a significant increase in revenue for the nine months ended September 30, 2025, reaching $126,904 thousand, up from $90,831 thousand in the prior year, representing a 39.7% increase. Despite this revenue growth, the company's net loss widened to $92,396 thousand for the nine-month period in 2025, compared to a net loss of $63,451 thousand in 2024. This increased loss was primarily driven by a substantial 'Change in fair value of common stock warrant liability' of $34,586 thousand in 2025, up from $4,490 thousand in 2024, and a 'Loss on extinguishment of debt' of $6,360 thousand. Operating expenses also rose, with 'Selling, general and administrative' expenses increasing to $96,197 thousand from $82,125 thousand. The company's cash and cash equivalents dramatically increased to $291,167 thousand as of September 30, 2025, from $51,367 thousand at December 31, 2024, largely due to an IPO which converted redeemable convertible preferred stock and convertible notes to common stock, and raised $332,318 thousand net of underwriting discounts. Total assets grew to $364,398 thousand from $118,704 thousand over the same period.

Why It Matters

Heartflow's substantial revenue growth of nearly 40% signals strong market adoption for its medical technology, which is crucial for a growth-stage company. However, the widening net loss, exacerbated by a significant increase in common stock warrant liability and debt extinguishment costs, raises concerns about profitability and valuation for investors. The successful IPO and subsequent cash infusion of over $332 million provide a critical lifeline, enabling further investment in R&D and market expansion, potentially intensifying competition in the medical diagnostics sector. Employees may see increased job security and growth opportunities, while customers could benefit from continued innovation in cardiac care.

Risk Assessment

Risk Level: high — The company reported a net loss of $92,396 thousand for the nine months ended September 30, 2025, a significant increase from $63,451 thousand in the prior year. This widening loss, coupled with a substantial 'Change in fair value of common stock warrant liability' of $34,586 thousand, indicates ongoing operational losses and potential dilution risks, despite a strong cash position post-IPO.

Analyst Insight

Investors should closely monitor Heartflow's path to profitability and the impact of its increased cash reserves on future operating expenses and R&D. While the IPO provides a strong balance sheet, sustained losses and the volatility of warrant liabilities warrant caution. Consider waiting for evidence of improved operational efficiency and reduced net losses before making a significant investment.

Financial Highlights

debt To Equity

N/A

revenue

$126.9M

operating Margin

N/A

total Assets

$364.4M

total Debt

N/A

net Income

-$92.4M

eps

N/A

gross Margin

N/A

cash Position

$291.2M

revenue Growth

+39.7%

Key Numbers

• $126.9M — Revenue (Increased 39.7% for the nine months ended September 30, 2025, from $90.8M in 2024.)
• $92.4M — Net Loss (Widened for the nine months ended September 30, 2025, from $63.5M in 2024.)
• $34.6M — Common Stock Warrant Liability Change (Significant increase in fair value change for the nine months ended September 30, 2025, from $4.5M in 2024.)
• $291.2M — Cash and Cash Equivalents (Increased substantially from $51.4M at December 31, 2024, primarily due to IPO proceeds.)
• $332.3M — IPO Proceeds (Net proceeds from the issuance of common stock upon IPO.)
• 83,473,696 — Common Shares Outstanding (As of September 30, 2025, significantly up from 6,122,048 at December 31, 2024, due to IPO and conversions.)
• $6.4M — Loss on Debt Extinguishment (Incurred during the nine months ended September 30, 2025.)
• $15.2M — Interest Expense (For the nine months ended September 30, 2025, down from $17.6M in 2024.)

Key Players & Entities

• Heartflow, Inc. (company) — Registrant
• Nasdaq Stock Market LLC (company) — Exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• $126,904 thousand (dollar_amount) — Revenue for nine months ended September 30, 2025
• $90,831 thousand (dollar_amount) — Revenue for nine months ended September 30, 2024
• $92,396 thousand (dollar_amount) — Net loss for nine months ended September 30, 2025
• $63,451 thousand (dollar_amount) — Net loss for nine months ended September 30, 2024
• $34,586 thousand (dollar_amount) — Change in fair value of common stock warrant liability for nine months ended September 30, 2025
• $6,360 thousand (dollar_amount) — Loss on extinguishment of debt for nine months ended September 30, 2025
• $291,167 thousand (dollar_amount) — Cash and cash equivalents as of September 30, 2025

FAQ

Risk Factors

• Common Stock Warrant Liability Volatility [medium — financial]: The company experienced a significant increase in the change of fair value of its common stock warrant liability, rising to $34,586 thousand for the nine months ended September 30, 2025, from $4,490 thousand in the prior year. This volatility can materially impact net income and earnings per share.
• Loss on Extinguishment of Debt [low — financial]: Heartflow incurred a $6,360 thousand loss on extinguishment of debt during the nine months ended September 30, 2025. While this is a non-recurring item, it contributed to the widened net loss.
• Increasing Operating Expenses [medium — operational]: Selling, general, and administrative expenses increased to $96,197 thousand for the nine months ended September 30, 2025, from $82,125 thousand in the prior year. Continued increases in operating expenses without commensurate revenue growth could pressure profitability.

Industry Context

The medical device industry, particularly in areas like cardiovascular diagnostics, is characterized by rapid innovation, significant R&D investment, and a complex regulatory approval process. Companies often face intense competition and require substantial capital to scale operations and commercialize new technologies.

Regulatory Implications

As a medical device company, Heartflow is subject to stringent regulations from bodies like the FDA. Compliance with quality standards, clinical trial requirements, and post-market surveillance is critical and can involve significant costs and potential delays.

What Investors Should Do

1. Monitor operating expense trends relative to revenue growth.
2. Analyze the impact of non-recurring items on net income.
3. Evaluate the use of increased cash reserves.

Key Dates

• 2025-09-30: Nine Months Ended — Reported significant revenue growth of 39.7% but a widened net loss, impacted by warrant liability changes and debt extinguishment.
• 2025-09-30: IPO Completion — Resulted in a substantial increase in cash and cash equivalents to $291.2M and a significant rise in common shares outstanding.
• 2024-12-31: Year End — Company had $51.4M in cash and cash equivalents and $136.4M in term loan debt.

Glossary

Common stock warrant liability

A financial instrument that gives the holder the right, but not the obligation, to purchase shares of common stock at a specified price within a certain timeframe. Changes in fair value are recognized in earnings. (A significant increase in its fair value change ($34.6M) negatively impacted net income in the current period.)

Loss on extinguishment of debt

A loss recognized when a company repays or retires its debt before its scheduled maturity date, often involving a premium payment or unamortized issuance costs. (Contributed to the widened net loss for the nine months ended September 30, 2025, amounting to $6.4M.)

Redeemable convertible preferred stock

A class of stock that has features of both preferred stock (e.g., dividend preference) and common stock (e.g., conversion rights), with an added feature allowing redemption by the holder under certain conditions. (This type of stock was converted to common stock as part of the IPO, impacting the equity structure and cash position.)

Year-Over-Year Comparison

Heartflow has demonstrated impressive revenue growth, increasing by 39.7% for the nine months ended September 30, 2025, compared to the prior year. However, this top-line expansion has been overshadowed by a widening net loss, primarily due to a significant increase in the change of fair value of common stock warrant liability and a loss on debt extinguishment. Operating expenses, specifically SG&A, have also risen. The company's financial position has been dramatically strengthened by its IPO, leading to a substantial increase in cash and total assets, while reducing its term loan debt.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share HTFL The Nasdaq

Filing Documents

• htfl-20250930.htm (10-Q) — 4178KB
• exhibit311-q3202510xq.htm (EX-31.1) — 10KB
• exhibit312-q3202510xq.htm (EX-31.2) — 11KB
• exhibit321-q3202510xq.htm (EX-32.1) — 5KB
• exhibit322-q3202510xq.htm (EX-32.2) — 5KB
• 0001464521-25-000019.txt ( ) — 15580KB
• htfl-20250930.xsd (EX-101.SCH) — 65KB
• htfl-20250930_cal.xml (EX-101.CAL) — 78KB
• htfl-20250930_def.xml (EX-101.DEF) — 313KB
• htfl-20250930_lab.xml (EX-101.LAB) — 807KB
• htfl-20250930_pre.xml (EX-101.PRE) — 609KB
• htfl-20250930_htm.xml (XML) — 3005KB

: Financial Information

Part I: Financial Information 4 Item 1. Condensed Consolidated Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations and Comprehensive Loss 5 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of

Management's Discussion and Analysis of Financial Condition and Results of Operations 40 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 52 Item 4.

Controls and Procedures

Controls and Procedures 53

: Other Information

Part II: Other Information 54 Item 1.

Legal Proceedings

Legal Proceedings 54 Item 1A.

Risk Factors

Risk Factors 54 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 104 Item 3. Defaults Upon Senior Securities 104 Item 4. Mine Safety Disclosures 104 Item 5. Other Information 104 Item 6. Exhibits 106

SIGNATURES

SIGNATURES 107 3 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. We intend such forward-looking statements contained in this Quarterly Report on Form 10-Q to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management, and expected market growth, are forward-looking statements. In some cases, you can identify

forward-looking statements by words such as "may," "will," "shall," "should," "expects," "plans," "anticipates,"

forward-looking statements by words such as "may," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions.

Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to,

Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, products, anticipated product launches, the impact of macroeconomic conditions, industry and business trends, and our expectations regarding business strategy, plans, market growth, regulatory climate, competitive landscape and our objectives for future operations. You should not rely on forward-looking statements as predictions of future events. We have based the forward- looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations, estimates, forecasts, and projections about future events and trends that we believe may affect our business, financial condition, results of operations, and prospects. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking uncertainties and are subject to other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those factors discussed in Part II, Item 1A, "Risk Factors" in this Quarterly Report on Form 10-Q, as such risks and uncertainties may be amended, supplemented or superseded from time to time by our subsequent periodic reports on Form 10-Q and Form 10-K we file with the United States Securities and Exchange Commission. We qualify all of our forward-looking

Financial Information

Part I. Financial Information

Condensed Consolidated Financial Statements (unaudited)

Item 1. Condensed Consolidated Financial Statements (unaudited) Heartflow, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) (unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents ........................................................................................................ $ 291,167 $ 51,367 Accounts receivable, net ............................................................................................................. 27,858 24,639 Restricted cash, current .............................................................................................................. — 150 Prepaid expenses and other current assets ............................................................................ 8,761 6,132 Total current assets ............................................................................................................... 327,786 82,288 Property and equipment, net ............................................................................................................ 7,984 8,920 Operating lease right-of-use assets, net ........................................................................................ 17,108 18,805 Restricted cash, non-current ............................................................................................................ 4,475 4,325 Other non-current assets .................................................................................................................. 7,045 4,366 Total assets ............................................................................................................................. $ 364,398 $ 118,704 Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Current liabilities: Accounts payable .............................................................................

View Full Filing

View this 10-Q filing on SEC EDGAR